Literature DB >> 24401474

Effect of Imatinib Coadministration on in Vitro Oocyte Acquisition and Subsequent Embryo Development in Cyclophosphamide-Treated Mice.

Eun Kyung Chun1, Byung Chul Jee2, Ju Yeong Kim3, Seok Hyun Kim4, Shin Yong Moon5.   

Abstract

The study aimed to investigate the effect of imatinib coadministration on in vitro oocyte acquisition and subsequent embryo development in cyclophosphamide (Cp)-treated mice. Female BDF1 mice were injected with 5 IU equine chorionic gonadotropin (eCG) followed by 5 IU human chorionic gonadotropin 48 hours later and then oocytes were retrieved 14 hours later. Twenty-four hours prior to eCG administration, 25, 50, or 75 mg/kg Cp with or without 7.5 mg/kg imatinib was injected. In the 25 and 50 mg/kg Cp groups, imatinib coadministration significantly enhanced the percentage of mature oocytes (+16.4% and +10.4%) and significantly decreased the percentage of dead oocytes (-25.9% and -15.3%). Imatinib coadministration significantly enhanced the fertilization rate (FR) in the 50 mg/kg Cp group (+12.2%). Intraoocyte spindle integrity was significantly affected by Cp and was rescued by imatinib coadministration. Coadministration of imatinib prior to ovarian stimulation has the benefit of enhancing oocyte maturity and the in vitro FR in Cp-treated mice .
© The Author(s) 2013.

Entities:  

Keywords:  blastocyst; cyclophosphamide; imatinib; in vitro fertilization

Year:  2014        PMID: 24401474      PMCID: PMC4107565          DOI: 10.1177/1933719113518986

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  23 in total

1.  Effect of paclitaxel on primordial follicular reserve in mice.

Authors:  F Gücer; P Balkanli-Kaplan; L Doganay; M A Yüce; E Demiralay; N C Sayin; T Yardim
Journal:  Fertil Steril       Date:  2001-09       Impact factor: 7.329

2.  Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations.

Authors:  D Meirow; M Epstein; H Lewis; D Nugent; R G Gosden
Journal:  Hum Reprod       Date:  2001-04       Impact factor: 6.918

3.  Effects of amifostine in combination with cyclophosphamide on female reproductive system.

Authors:  Zeinab Barekati; Afsaneh Golkar-Narenji; Mehdi Totonchi; Ramin Radpour; Hamid Gourabi
Journal:  Reprod Sci       Date:  2012-01-19       Impact factor: 3.060

Review 4.  Roles of reactive oxygen species and antioxidants in ovarian toxicity.

Authors:  Patrick J Devine; Sally D Perreault; Ulrike Luderer
Journal:  Biol Reprod       Date:  2012-02-09       Impact factor: 4.285

5.  Differential expression of p63 isoforms in female reproductive organs.

Authors:  Takeshi Kurita; Gerald R Cunha; Stanley J Robboy; Alea A Mills; Roanna T Medina
Journal:  Mech Dev       Date:  2005-09       Impact factor: 1.882

6.  Aneuploidy determination in C-banded mouse metaphase II oocytes following cyclophosphamide treatment in vivo.

Authors:  Z P Yuan; J B Mailhes
Journal:  Mutat Res       Date:  1987-08       Impact factor: 2.433

7.  Effect of cyclophosphamide on mouse oocyte in vitro fertilization and cleavage: recovery.

Authors:  E F Pydyn; K M Ataya
Journal:  Reprod Toxicol       Date:  1991       Impact factor: 3.143

8.  Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.

Authors:  A F List; R Heaton; B Glinsmann-Gibson; R L Capizzi
Journal:  Semin Oncol       Date:  1996-08       Impact factor: 4.929

9.  Previous maternal chemotherapy by cyclophosphamide (Cp) causes numerical chromosome abnormalities in preimplantation mouse embryos.

Authors:  Zeinab Barekati; Hamid Gourabi; Mojtaba Rezazadeh Valojerdi; Poopak Eftekhari Yazdi
Journal:  Reprod Toxicol       Date:  2008-10-15       Impact factor: 3.143

10.  The beneficial effects of antifreeze proteins in the vitrification of immature mouse oocytes.

Authors:  Jun Woo Jo; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.